期刊
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
卷 12, 期 2, 页码 159-166出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERP.12.8
关键词
adherence; compliance; cost-effectiveness; economic; osteoporosis; persistence
资金
- Amgen
- Novartis
- Servier
- Pfizer
- Abbott Pharma
- Negma
- Lilly
- Wyeth
- GlaxoSmithKline
- Roche
- Merckle
- Nycomed
- NPS
- Theramex
- UCB
- Merck Sharp
- Rottapharm
- IBSA
- Genevrier
- Teijin
- Teva
- Ebewee Pharma
- Zodiac
- Analis
- Novo Nordisk
- Bristol Myers Squibb
- Dohme
Adherence to medications is poor and suboptimal in many chronic diseases. Nonadherence can reduce treatment effectiveness and can have an impact on healthcare costs. As a consequence, it may alter the cost effectiveness of drug therapies. This article emphasizes the importance of integrating medication compliance and persistence into pharmacoeconomic evaluations, using osteoporosis as an example. A limited number of studies carried out to date have suggested important economic implications of poor adherence to osteoporosis medications. Therefore, compliance and persistence should be an integral part of clinical studies and pharmacoeconomic analyses in order to estimate the cost effectiveness of drug therapies in current community practice. Measuring adherence and incorporating it into health economic modeling may, however, pose particular challenges.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据